bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 7,000 shares of the stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $166.64, for a total transaction of $1,166,480.00. Following the sale, the insider now directly owns 31,905 shares in the company, valued at approximately $5,316,649.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

David Davidson also recently made the following trade(s):

  • On Wednesday, July 11th, David Davidson sold 3,000 shares of bluebird bio stock. The shares were sold at an average price of $180.15, for a total transaction of $540,450.00.
  • On Monday, July 2nd, David Davidson sold 10,000 shares of bluebird bio stock. The shares were sold at an average price of $153.96, for a total transaction of $1,539,600.00.

Shares of NASDAQ BLUE traded down $1.45 during mid-day trading on Friday, hitting $150.85. 17,646 shares of the company were exchanged, compared to its average volume of 425,299. bluebird bio Inc has a 1-year low of $119.90 and a 1-year high of $236.17. The company has a market cap of $8.74 billion, a PE ratio of -19.75 and a beta of 1.86.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Thursday, August 2nd. The biotechnology company reported ($2.91) EPS for the quarter, missing analysts’ consensus estimates of ($2.30) by ($0.61). bluebird bio had a negative net margin of 1,281.01% and a negative return on equity of 31.57%. The business had revenue of $7.80 million during the quarter, compared to analyst estimates of $10.68 million. During the same period last year, the business posted ($1.73) EPS. bluebird bio’s revenue was down 53.3% compared to the same quarter last year. research analysts expect that bluebird bio Inc will post -10.78 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC lifted its holdings in bluebird bio by 1.9% in the second quarter. Jennison Associates LLC now owns 512,740 shares of the biotechnology company’s stock valued at $80,475,000 after acquiring an additional 9,677 shares during the period. Xact Kapitalforvaltning AB lifted its holdings in bluebird bio by 12.3% in the second quarter. Xact Kapitalforvaltning AB now owns 7,330 shares of the biotechnology company’s stock valued at $1,150,000 after acquiring an additional 800 shares during the period. Creative Planning acquired a new stake in bluebird bio in the second quarter valued at $381,000. Schwab Charles Investment Management Inc. lifted its holdings in bluebird bio by 12.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 332,536 shares of the biotechnology company’s stock valued at $56,781,000 after acquiring an additional 36,463 shares during the period. Finally, Daiwa Securities Group Inc. lifted its holdings in bluebird bio by 38.4% in the second quarter. Daiwa Securities Group Inc. now owns 15,515 shares of the biotechnology company’s stock valued at $2,435,000 after acquiring an additional 4,306 shares during the period. 98.38% of the stock is owned by institutional investors.

Several brokerages recently weighed in on BLUE. Cowen reaffirmed a “buy” rating on shares of bluebird bio in a report on Monday, August 6th. Cantor Fitzgerald set a $122.00 target price on shares of bluebird bio and gave the company a “sell” rating in a report on Wednesday. BMO Capital Markets reaffirmed a “buy” rating and issued a $208.00 target price on shares of bluebird bio in a report on Friday, August 3rd. Piper Jaffray Companies reaffirmed a “buy” rating on shares of bluebird bio in a report on Thursday, August 2nd. Finally, Maxim Group reduced their target price on shares of bluebird bio to $163.00 and set a “hold” rating on the stock in a report on Monday, July 30th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $212.05.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

See Also: How Important is Technical Analysis of Stocks

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.